FindTrial
Sign In

The efficacy and safety of azvudine in the treatment of SRAS-COV-2 infection: a retrospective medical based study

The efficacy and safety of azvudine in the treatment of SRAS-COV-2 infection: a retrospective medical based study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072963
Enrollment
Unknown
Registered
2023-06-28
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

azvudine treatment group:N/A
without azvudine treatment group:N/A

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Patients discharged from the study unit with SRAS-COV-2 infection from December 2022 to January 2023 2) =18 years old

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women 2) Patients with cirrhosis on admission or with elevated aminotransferase levels greater than five times the upper limit of normal 3) Severe renal impairment on admission (estimated renal function < 30 mL/min/1.72 m2) or dialysis patients 4) Patients who died within 24 hours of admission 5) Patients receiving HIV antiviral treatment

Design outcomes

Primary

MeasureTime frame
Length of stay;—

Secondary

MeasureTime frame
COVID-19 RT-PCR negative convertion time;—

Countries

China

Contacts

Public ContactHong Cheng

Zhongnan Hospital of Wuhan University

chenghong@znhospital.cn+86 133 8766 0579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026